Should I buy Jazz Pharmaceuticals (JAZZ) stock or is it too late?
⭐ The most reliable of them, either direction: B of A Securities — 74% of its targets hit on this sector (105 calls tested). It aims for $307 (+22 %), call made on June 11, 2026, maturing on June 11, 2027 (78 d ago).
Firm-by-firm track record on Jazz Pharmaceuticals
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| B of A Securities | 60 % | +58.3 % | 5 | $307 +22% |
| Piper Sandler | 69 % | +37.2 % | 13 | $310 +23% |
| UBS | 60 % | +31.4 % | 10 | $307 +22% |
| Cantor Fitzgerald | 70 % | +24.6 % | 10 | $140 -44% |
| Needham | 64 % | +23.1 % | 28 | $292 +16% |
| JP Morgan | 100 % | +22.3 % | 6 | $276 +10% |
| Wells Fargo | 86 % | +18.5 % | 7 | $300 +19% |
| RBC Capital | 62 % | +14.7 % | 16 | $258 +3% |
✅ Reasons to believe
- 94% of analysts rate it a buy (Buy consensus, 16 ratings) — a sign of market conviction.
- Median price target $282, i.e. +12% from the current price ($251).
- The most reliable firm on JAZZ, JP Morgan (100% hit rate, 6 scored calls), targets $276 (call made on August 4, 2026, maturing on August 4, 2027) (+10%) in its most recent call, and $199 (call made on October 27, 2025, maturing on October 27, 2026) (-21%) in the one coming due soonest.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 16 ratings, 1 is neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on JAZZ
Median target $282 (+12%) · 16 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Jazz Pharmaceuticals now?
We won't decide for you. The facts: 94% of analysts rate it a buy, median target $282 (+12%), and JP Morgan (most reliable on JAZZ, 100%) targets $276. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Jazz Pharmaceuticals?
Not according to analysts: the median target ($282) is still +12% above the current price ($251) (most reliable on JAZZ: JP Morgan, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Jazz Pharmaceuticals still worth investing in?
It depends on the gap between the price ($251) and its estimated value: analysts target $282 on median (+12%), with 94% buys (most reliable on JAZZ: JP Morgan, 100%). Cross-check with their real reliability on JAZZ and the cautions above. Information, not advice.
What's the main risk in buying JAZZ?
The consensus is not unanimous: of 16 ratings, 1 is neutral.
→ Go deeper: the full Jazz Pharmaceuticals profile (consensus, analyst reliability, price target, performance).